Skip to main content
Premium Trial:

Request an Annual Quote

Lipomics to Help Isis Pharma Test Compounds for Metabolic Drug Trials

NEW YORK (GenomeWeb News) — Lipomics today said it will provide its lipid metabolite services to Isis Pharmaceuticals.
 
Under the terms of the agreement, Lipomics will support Isis in its pre-clinical and clinical trials of lipid compounds that may be used to treat metabolic diseases.
 
Lipomics said it will hold exclusive rights to develop diagnostics that result from the research, while Isis will retain rights to therapeutics.
 
Lipomics’ model “focuses on providing plasma-based mechanistic markers of lipid metabolism,” said president and CSO Steve Watkins.
 
Financial terms of the agreement were not released.
 
On Monday, Lipomics said it signed an agreement to use Agilent Technologies’ biomarker-based assays for its metabolic analytical research.